|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lunasin may act as a potential therapeutic agent for the prevention and treatment of atherosclerosis.-Gu, L., Ye, P., Li, H., Wang, Y., Xu, Y., Tian, Q., Lei, G., Zhao, C., Gao, Z., Zhao, W., Tan, S. Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE<sup>-/-</sup> mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway.
|
30601695 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In animal models, a lack of HO-1 was shown to accelerate atherosclerosis, whereas HO-1 induction reduced atherosclerosis.
|
31344980 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we focus on the translational potential of HIERS and heme oxygenase-1 (HO-1) in atherosclerosis, diabetes mellitus, and brain hemorrhage.
|
31357546 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since these products have antiatherogenic properties, HO-1 may play a protective role against the progression of atherosclerosis.
|
30159103 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heme oxygenase 1 (HO-1) protects against inflammatory processes such as ischemia-reperfusion injury (IRI), organ transplantation, and atherosclerosis.
|
30282830 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because these products have antiatherogenic properties, HO-1 may play a protective role against atherosclerosis.
|
30354985 |
2018 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We reported previously that the flavonoid quercetin protects arteries from oxidant-induced endothelial dysfunction and attenuates atherosclerosis in apolipoprotein E gene knockout mice, with induction of heme oxygenase-1 (Hmox1) playing a critical role.
|
28970059 |
2017 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with ≥32 tandem repeats on both HO-1 alleles compared with the rest of the population (recessive trait) featured substantially increased cardiovascular disease risk (hazard ratio [95% confidence interval], 5.45 [2.39, 12.42]; P<0.0001), enhanced atherosclerosis progression (median difference in atherosclerosis score [interquartile range], 2.1 [0.8, 5.6] versus 0.0 [0.0, 2.2] mm; P=0.0012), and a trend toward higher levels of oxidized phospholipids on apolipoprotein B-100 (median oxidized phospholipids/apolipoprotein B level [interquartile range], 11364 [4160, 18330] versus 4844 [3174, 12284] relative light units; P=0.0554).
|
25359861 |
2015 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we demonstrated that EI induced oxidative stress in endothelial cells leading to increased expression of oxidative stress response gene OKL38 and HO-1 via Nrf2 signaling pathway relevant to atherosclerosis.
|
24434148 |
2014 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We undertook this study to investigate whether HO-1 gene rs2071746 polymorphism was associated with clinical outcomes in atherosclerosis ischemic stroke patients.
|
25016572 |
2014 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether S. platensis or phycocyanobilin (PCB), its tetrapyrrolic chromophore, can activate atheroprotective heme oxygenase-1 (Hmox1), a key enzyme in the heme catabolic pathway responsible for generation of a potent antioxidant bilirubin, in endothelial cells and in a mouse model of atherosclerosis.
|
24056745 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protective role of heme oxygenase-1 against inflammation in atherosclerosis.
|
21622183 |
2011 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of atherosclerosis and the HO-1 genetic variants was assessed by a logistic regression analysis, adjusted for cardiovascular risk factors.
|
20796278 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological induction or gene transfer of HO-1 ameliorates vascular dysfunction in animal models of atherosclerosis, post-angioplasty restenosis, vein graft stenosis, thrombosis, myocardial infarction, and hypertension, while inhibition of HO-1 activity or gene deletion exacerbates these disorders.
|
20704550 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beneficial activities of HO-1 have been recognized in many pathological states e.g. atherosclerosis, diabetes, ischemia/reperfusion injury or organ transplantation.
|
20704546 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of HO-1 overexpression with a greater extent of intraplaque angiogenesis suggests a multi-faceted role for HO-1 in modulating the progression of atherosclerosis.
|
18620357 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Great attention has been placed on the protective role of heme oxygenase-1 (HO-1) for several vascular diseases such as atherosclerosis.
|
18289069 |
2008 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated that HO-1 expression and activity in ECs are present only in advanced atherosclerosis whereas, VEGF expression is present in early as well as in advanced atherosclerosis and the degree of its expression increases with severity of atherosclerosis.
|
16999951 |
2006 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study demonstrated that HO-1 expression and activity in ECs are present only in advanced atherosclerosis whereas, VEGF expression is present in early as well as in advanced atherosclerosis and the degree of its expression increases with severity of atherosclerosis.
|
16999951 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inducible heme oxygenase-1 and downstream proteins biliverdin reductase and p21, a cyclin-dependent kinase, were up-regulated, potentially contributing to phenotypic heterogeneity and absence of atherosclerosis in patients with sickle cell disease despite endothelial dysfunction and vascular inflammation.
|
15031206 |
2004 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heme oxygenase-1 (HO-1) has been demonstrated to exert potent anti-oxidant and anti-inflammatory effects in the context of atherosclerotic vascular disease, and therefore was referred to as a potential vascular protective factor.
|
15140586 |
2004 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Elucidation of the molecular mechanisms which control HO-1 gene expression will allow us to develop therapeutic strategies to enhance the cytoprotective potential of HO-1 in atherosclerosis.
|
12805077 |
2003 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that the overexpression of introduced hHO-1 is potentially able to reduce the risk factors of atherosclerosis, partially due to its cellular protection against oxidative injury and to its inhibitory effect on cellular proliferation.
|
12118938 |
2002 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with AAA were less frequently carriers of short (< 25 GT) repeats in the HO-1 gene promoter than patients with atherosclerosis or healthy subjects.
|
12182912 |
2002 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Patients with AAA were less frequently carriers of short (< 25 GT) repeats in the HO-1 gene promoter than patients with atherosclerosis or healthy subjects.
|
12182912 |
2002 |